PharmAbcine Obtains New Patent Related to EGFRvIII Antibody
[Asia Economy Reporter Minwoo Lee] PharmAbcine announced on the 21st that it has obtained a patent for 'New EGFRvIII Antibody and Compositions Containing the Same.'
Hot Picks Today
![Cracks in Samsung and SK hynix’s Duopoly?... Micron’s Bet with the ‘100,000 HBM Wafers’ Bomb [ChipTalk]](https://cwcontent.asiae.co.kr/asiaresize/93/2025072814474862132_1753681669.jpg)
Cracks in Samsung and SK hynix’s Duopoly?... Micron’s Bet with the ‘100,000 HBM Wafers’ Bomb [ChipTalk]
- "The Effects of 'Perfect Beauties' on Mental Health: Just How Harmful Are Unrealistic Standards? [Experiment Note]"
- "We'll Fold It Three Times"... Samsung Takes a Jab at Apple's iPhone Duo
- "Samsung Electronics' Employee Benefits Ignite Housing Price Surge... 'Samsung Effect' Pushes Neighborhood Past 900 Million Won [Real Estate AtoZ]"
- "Don't Send Your Kids to School": Jung Hyungdon Explains His Conviction
The company stated, "This patent relates to an antibody that does not cross-react with EGFR but specifically binds to EGFRvIII, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumors containing the antibody as an active ingredient." They explained, "EGFRvIII is a target expressed only in tumors and not in normal cells, and it can be utilized in the development of therapeutics such as antibody-drug conjugates (ADC), CAR-T, CAR-NK, CAR-Macrophage, and bispecific antibodies."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
